Free Trial
NASDAQ:IMCR

Immunocore Q1 2025 Earnings Report

Immunocore logo
$32.22 -0.02 (-0.06%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$32.20 -0.02 (-0.06%)
As of 08/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunocore EPS Results

Actual EPS
$0.10
Consensus EPS
-$0.35
Beat/Miss
Beat by +$0.45
One Year Ago EPS
-$0.49

Immunocore Revenue Results

Actual Revenue
$125.13 million
Expected Revenue
$108.82 million
Beat/Miss
Beat by +$16.32 million
YoY Revenue Growth
+33.60%

Immunocore Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Immunocore's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunocore Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Immunocore Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email.

About Immunocore

Immunocore (NASDAQ:IMCR) Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

View Immunocore Profile

More Earnings Resources from MarketBeat